Table 1:
Antibody panels used for flow cytometric analysis in this study
| Panel | Blue laser (488 nm 50 mw) |
Red laser (640 nm 40 mw) |
Violet laser (405 nm 50 mw) |
UV laser (355 nm 60 mw) |
Purpose | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 530/30 | 575/26 | 695/40 | 780/60 | 670/14 | 780/60 | 450/50 | 525/50 | 610/20 | 379/28 | ||
| 1. | CD38 FITC | Testa | CD45 PCPCy5.5 | CD19 PECy7 | CD56 APC | CD4 APCH7 | CD138 BV421 | CD3 BV510 | CD14 BV605 | CD8 BUV395 | Test expression of markers on various leukocyte subsets |
| 2. | p63 FITC | CD56 PE | CD45 PCPCy5.5 | CD19 PECy7 | - | - | CD138 BV421 | CD38 BV510 | CD14 BV605 | CD3 BUV395 | Test expression of p63 in plasma cells |
| 3. | CD38 FITC | CD229 PE | CD45 PCPCy5.5 | - | CD319 APC | - | - | - | - | CD138 BUV395 | Test stability of markers after storage |
| 4. | CD38 FITC | CD229 PE | CD45 PCPCy5.5 | CD19 PECy7 | CD319 APC | CD81 APCH7 | CD56 BV421 | CD27 BV510 | CD117 BV605 | CD138 BUV395 | Test ability of CD229 and CD319 to distinguish PCs in samples treated with daratumumab and elotuzumab |
| 5. | CD56 BB515 | Antibody cocktailb | CD45 PCPCy5.5 | CD19 PECy7 | CD117 APC | CD81 APCH7 | CD138 BV421 | CD27 BV510 | - | - | Test CD38/CD319 combination in a myeloma MRD panel |
a
A total of 15 surface antigens were tested in this study. All antibodies were conjugated to PE. These antigens were CD29, CD40, CD47, CD48, CD54, CD229, CD269, CD317, CD307, CD353, CD84, CD150, CD244, CD319, and CD352
b
Containing CD38 PE and/or CD319 PE